Japan commits to pricing reforms and to shortening drug review times
This article was originally published in SRA
Executive Summary
A report from the US-Japan Regulatory Reform and Competition Policy Initiative outlines a host of measures that Japanese regulators have initiated recently, or that are in the pipeline, to shorten their review times for pharmaceuticals and medical devices and enhance Japanese patient access to US products1-3.